New draft guidance from the National Institute for Health and Care Excellence (NICE) and a separate review by NHS England have both underscored a significant gap in the evidence base for cannabis-based medicinal products (CBMPs). Both organisations highlight the pressing need for more rigorous research to determine the efficacy and safety of these treatments, which could pave the way for broader clinical use within the National Health Service.
NICE's draft recommendations indicate that there is currently insufficient high-quality evidence to recommend most CBMPs for a wide range of conditions. While some specific products have received limited recommendations for certain conditions, such as severe forms of epilepsy or multiple sclerosis-related spasticity, the overall picture reveals a substantial lack of robust clinical trials to support their widespread adoption. This creates a challenging landscape for both prescribers and patients.
Echoing these concerns, NHS England's review independently arrived at similar conclusions, stressing that the absence of comprehensive data makes it difficult for clinicians to make informed decisions about prescribing. The review points out that without this evidence, it is challenging to assess the true benefits, potential risks, and appropriate dosing regimens for many cannabis-based treatments. This consensus from two key health bodies signals a critical juncture for the future of medicinal cannabis in the UK.
The current situation means that while medicinal cannabis was legalised in the UK in November 2018, access through the NHS remains highly restricted. Patients often face significant barriers, including high costs for private prescriptions, due to the limited number of conditions for which NHS doctors are currently permitted to prescribe these products. The call for more research is therefore not just an academic exercise but a practical necessity to address patient needs and expand treatment options responsibly.
Stakeholders, including patient groups, medical professionals, and pharmaceutical companies, are now urged to contribute to the development of better evidence. This could involve funding more clinical trials, facilitating data collection, and collaborating on research initiatives. The ultimate goal is to build a robust evidence base that allows NICE to issue more definitive guidance and for NHS England to incorporate these treatments into mainstream care where appropriate.